Cited by 3,238Nutrition and Health in AgingBody Composition Measurement TechniquesFrailty in Older Adults

Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study

Prado, Carla MM, Lieffers, Jessica R, McCargar, Linda J, Reiman, Tony, Sawyer, Michael B, Martin, Lisa, Baracos, Vickie E·2008·The Lancet Oncology

Abstract

Background Emerging evidence on body composition suggests that sarcopenic obesity (obesity with depleted muscle mass) might be predictive of morbidity and mortality in non-malignant disease and also of toxicity to chemotherapy. We aimed to assess the prevalence and clinical implications of sarcopenic obesity in patients with cancer. Methods Between Jan 13, 2004, and Jan 19, 2007, 2115 patients with solid tumours of the respiratory or gastrointestinal tract from a cancer treatment centre serving northern Alberta, Canada, were identified. Available lumbar CT images of the obese patients were analysed for total skeletal muscle cross-sectional area; these values were also used to estimate total body fat-free mass (FFM). Findings Of the 2115 patients initially identified, 325 (15%) were classified as obese (body-mass index [BMI] > or =30). Of these obese patients, 250 had CT images that met the criteria for analysis. The remaining 75 patients were recorded as without assessable scans. Obese patients had a wide range of muscle mass. Sex-specific cut-offs that defined a significant association between low muscle mass with mortality were ascertained by optimum stratification analysis: 38 (15%) of 250 patients who had assessable CT images that met the criteria for analysis were below these cut-offs and were classified as having sarcopenia. Sarcopenic obesity was associated with poorer functional status compared with obese patients who did not have sarcopenia (p=0.009), and was an independent predictor of survival (hazard ratio [HR] 4.2 [95% CI 2.4-7.2], p<0.0001). Estimated FFM showed a poor association with body-surface area (r(2)=0.37). Assuming that FFM represents the volume of distribution of many cytotoxic chemotherapy drugs, we estimated that individual variation in FFM could account for up to three-times variation in effective volume of distribution for chemotherapy administered per unit body-surface area, in this population. Interpretation This study provides evidence of the great variability of body composition in patients with cancer and links body composition, especially sarcopenic obesity, to clinical implications such as functional status, survival, and potentially, chemotherapy toxicity.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(08)70153-0

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Both sarcopenia and sarcopenic obesity are recognized as important nutritional problems that place older adults at higher risk of morbidity and mortality.

    “Both sarcopenia and sarcopenic obesity, in which reduced FFM is combined with increased FM, are recognized as important nutritional problems that place older adults at higher risk of morbidity and mortality [2,29].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Prado, C. M., Lieffers, J. R., McCargar, L. J., Reiman, T., Sawyer, M. B., Martin, L., & Baracos, V. E.
Affiliations
University of Alberta (CA)
Corresponding author
Baracos, Vickie E
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2008-07
Volume
9
Issue
7
Pages
629-635
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2127424726
Cited by
3,238
References
7
Citations by year
2026: 247 · 2025: 256 · 2024: 289 · 2023: 273 · 2022: 300 · 2021: 341 · 2020: 297 · 2019: 248 · 2018: 238 · 2017: 160 · 2016: 146 · 2015: 142 · 2014: 103 · 2013: 59 · 2012: 56
FWCI
17.88
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Nutrition and Health in Aging
  • Health Sciences › Medicine › Physiology › Body Composition Measurement Techniques
  • Health Sciences › Medicine › Geriatrics and Gerontology › Frailty in Older Adults
Keywords
sarcopenic obesity, sarcopenia, body composition, skeletal muscle area, fat-free mass, respiratory cancer, gastrointestinal cancer, solid tumors, obesity, functional status, survival, chemotherapy toxicity, volume of distribution, cancer cachexia
MeSH terms
Adult, Aged, Aged, 80 and over, Alberta, Body Composition, Female, Gastrointestinal Neoplasms, Humans, Lung Neoplasms, Male, Middle Aged, Muscular Diseases, Obesity, Cohort Studies, Prevalence, Muscle, Skeletal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review